COL17A1 and early-onset autosomal dominant Alzheimer disease: A high frequency of serum response with human cutaneous BP180 protein was observed in 39.1% of patients with Alzheimer’s disease (39.1%) [63] and the serum from patients with Alzheimer’s disease also showed a high positive frequency response with BP180 protein in the extract from the human brain (47.8%) [63].